EXACT Therapeutics to Present at the Annual International Symposium on Therapeutic Ultrasound (ISTU 2024)

18 Sep 2024 20:30 CEST

Oslo, Norway, September 18, 2024 - EXACT Therapeutics AS (Euronext Growth:
EXTX), a clinical stage precision medicine company utilizing the power of
ultrasound to enable targeted drug delivery in oncology, today announced that it
will be giving two presentations at the upcoming 23rd Annual International
Symposium on Therapeutic Ultrasound, taking place September 19-22, 2024, in
Taipei, Taiwan. The company will be giving a virtual company presentation and in
addition, will be presenting a poster on Mechanistic Insights of Acoustic
Cluster Therapy (ACT®), EXACT’s unique ultrasound mediated oncology therapy.

Details of the company- and poster presentations are as follows:

Virtual Company presentation:

Title: Acoustic Cluster Therapy – clinical translation of a new microdroplet
drug delivery technology

Body Clinical Session on Saturday September 21st at 14:16 (local time) in room
101


Poster presentation:

Title: Mechanistic Insights of Acoustic Cluster Therapy (ACT®): Understanding
ACT Bubble Creation and Oscillation Behaviour

Poster Session on Friday September 20th at 15:00 (local time) on first floor of
TICC


The company presentation will be made available at the Investors section the
Company’s website: https://exact-tx.com/finreports and the poster will be made
available in the Research Papers section: https://exact-tx.com/publications-1-1
in parallel with the Session.





For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com





About EXACT Therapeutics

EXACT is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement – with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com



About ACT®
• ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.

• ACT is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic

enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as

well as blood-brain barrier penetration.

• Initial focus of the company is oncology. The ACT platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes.

Forward looking statements:

This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the

company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.

More information:
Access the news on Oslo Bors NewsWeb site

628070_280918 EXACT-TX_ISTU PR.pdf